Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation (Q34505579)

2 August 2017

5 references

22 March 2019

17 June 2019

17 September 2019

27 April 2021

19 January 2024

Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation (English)

1 reference

2 August 2017

3 references

22 March 2019

17 June 2019

17 September 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

27 April 2021

5

Juan Tamargo

1 reference

2 August 2017

4

Andreas Goette

1 reference

2 August 2017

Harry J. G. M. Crijns

series ordinal

3

object named as

Harry J Crijns

1 reference

2 August 2017

Etienne Aliot

1

1 reference

2 August 2017

Alessandro Capucci

series ordinal

2

1 reference

2 August 2017

language of work or name

1 reference

7 December 2010

1 reference

2 August 2017

1 February 2011

5 references

22 March 2019

17 June 2019

17 September 2019

27 April 2021

19 January 2024

6 references

2 August 2017

22 March 2019

17 June 2019

17 September 2019

27 April 2021

19 January 2024

13

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

161-173

1 reference

Creative Commons Attribution-NonCommercial 2.5 Generic

2 August 2017

copyright license

5 references

22 March 2019

17 June 2019

17 September 2019

27 April 2021

on focus list of Wikimedia project

19 January 2024

ScienceSource

0 references

cites work

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Impact of the control of symptomatic paroxysmal atrial fibrillation on health-related quality of life.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Chronic atrial fibrillation: a systematic review of medical heart rate control management.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Rhythm control versus rate control for atrial fibrillation and heart failure

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Rate control vs rhythm control strategies in atrial fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Pharmacology of cardiac potassium channels.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

A comparison of rate control and rhythm control in patients with atrial fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Dedifferentiation of atrial cardiomyocytes as a result of chronic atrial fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Histological substrate of atrial biopsies in patients with lone atrial fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting "Deadly Medicine" to the test

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Antiarrhythmic and electrophysiologic actions of flecainide in animal models.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

A proposal for the clinical use of flecainide

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

7 July 2018

Drug therapy. Flecainide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Proarrhythmia in patients treated for atrial fibrillation or flutter

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Effects of flecainide on the rate dependence of atrial refractoriness, atrial repolarization and atrioventricular node conduction in anesthetized dogs.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Secular trends in the prevalence of atrial fibrillation: The Framingham study

7 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Characteristics associated with physician discipline: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Myocardial cell death in fibrillating and dilated human right atria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Sodium accumulation during ischemia induces mitochondrial damage in perfused rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Cost-effectiveness of rhythm versus rate control in atrial fibrillation.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Meta-analysis of flecainide safety in patients with supraventricular arrhythmias

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Blocking Na(+)/H(+) exchange reduces [Na(+)](i) and [Ca(2+)](i) load after ischemia and improves function in intact hearts

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Management of new onset atrial fibrillation

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation

27 October 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

27 October 2018

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024037

Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension

27 October 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUQ382

Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias

21 January 2018

1 reference

12 December 2020

Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand

1 reference

12 December 2020

Cellular electrophysiological effects of flecainide on human atrial fibres

1 reference

12 December 2020

Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation

1 reference

12 December 2020

A comparison of the antiarrhythmic effects on AV junctional re-entrant tachycardia of oral and intravenous flecainide acetate

1 reference

12 December 2020

Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study

1 reference

12 December 2020

Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias

1 reference

12 December 2020

Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology

1 reference

12 December 2020

Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide

1 reference

12 December 2020

Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed

1 reference

12 December 2020

Atrial electrophysiologic remodeling: another vicious circle?

1 reference

12 December 2020

Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000

1 reference

12 December 2020

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

1 reference

12 December 2020

1 reference

12 December 2020

Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol

1 reference

12 December 2020

Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues

1 reference

12 December 2020

Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction

1 reference

12 December 2020

Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds

1 reference

12 December 2020

Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia

1 reference

12 December 2020

Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm

1 reference

12 December 2020

Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation

1 reference

12 December 2020

Effect of flecainide on cardiac output

1 reference

12 December 2020

Electrophysiologic properties of flecainide acetate

1 reference

12 December 2020

Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens

1 reference

12 December 2020

Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes

1 reference

12 December 2020

Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation

1 reference

12 December 2020

Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome

1 reference

12 December 2020

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation

1 reference

12 December 2020

A community education program on atrial fibrillation: implications of pulse self-examination on awareness and behavior

1 reference

12 December 2020

Oral flecainide acetate for the treatment of ventricular arrhythmias

1 reference

12 December 2020

Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat

1 reference

12 December 2020

Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment

1 reference

12 December 2020

Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans

1 reference

12 December 2020

Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery

1 reference

12 December 2020

Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent

1 reference

12 December 2020

Idiopathic atrial fibrillation in dogs: electrophysiologic determinants and mechanisms of antiarrhythmic action of flecainide

1 reference

12 December 2020

Decrease of right and left atrial sizes after direct-current electrical cardioversion in chronic atrial fibrillation

1 reference

12 December 2020

Influence of left ventricular dysfunction on flecainide therapy

1 reference

12 December 2020

Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial

1 reference

12 December 2020

Electrical remodeling in atrial fibrillation. Time course and mechanisms

1 reference

12 December 2020

Wavelength and conduction inhomogeneity in each atrium in patients with isolated mitral valve disease and atrial fibrillation

1 reference

12 December 2020

Identifiers

DOI

10.1093/EUROPACE/EUQ382

1 reference

2 August 2017

1 reference

2 August 2017

1 reference